Take-home methadone dosing: the federal limits clinics have to document

The 2024 rule replaced the old time-in-treatment ladder

SAMHSA's February 2, 2024 final rule on medications for opioid use disorder revised take-home standards. The rule was effective April 2, 2024, with a compliance date of October 2, 2024. Extra unsupervised methadone is now tied to clinical judgment and the caps in 42 CFR 8.12(i)(3), not to the older fixed schedule of one take-home after 90 days and so on.

This page summarizes the federal text so a clinic owner can see what the record must contain. It is not legal advice, not a state-by-state survey, and not a dosing recommendation.

What MASE does not claim

Health OS publishes a dosing-window workflow, dual-control inventory corrections, and human e-signature on overrides. MASE does not claim that Health OS calculates take-home eligibility, prints take-home labels, or files a take-home report to SAMHSA or a state agency.

A clinic can still use its EMR as the place the practitioner's rationale is stored. Whether a particular screen does that is a product question for a demo, not a claim this article makes. Start that conversation at https://www.mase.health/request-demo.

Steps

1. Separate closed-day doses from extra take-homes

   Any patient in comprehensive treatment may receive take-home doses for days the clinic is closed, including one weekend day and state and federal holidays, regardless of time in treatment. Doses beyond those closed days are a separate decision.

2. Have the right practitioner make the extra-dose decision

   Unsupervised doses beyond closed-clinic days are determined by an appropriately licensed OTP medical practitioner or the medical director. The decision has to weigh therapeutic benefit against risk.

3. Apply the criteria in 42 CFR 8.12(i)(2)

   The practitioner considers absence of active substance use disorders or other conditions that raise overdose or safety risk, regularity of attendance, absence of serious behavioral problems, absence of known recent diversion, whether the medication can be transported and stored safely, and any other criterion the practitioner considers relevant.

4. Stay inside the methadone supply caps

   For methadone, the extra take-home supply is limited to 7 days during the first 14 days of treatment, 14 days from day 15, and 28 days from day 31. The practitioner may choose fewer days. These caps do not apply to buprenorphine products listed in 42 CFR 8.12(h)(2)(ii). State law can be stricter than the federal cap.

5. Write the rationale in the clinical record

   The determination and its basis must be documented in the patient's medical record. For methadone, the rationale for unsupervised doses must be in the clinical record. The chart entry is the compliance artifact, not a verbal decision at the window.

6. Label, package, and educate

   Programs need procedures to identify theft or diversion, containers labeled with the OTP's name, address, and telephone number, and packaging designed to reduce accidental ingestion, including child-resistant containers. Patients are educated on safe transport and storage, and that education is documented.

Sources

• eCFR 42 CFR 8.12(i), unsupervised or take-home doses
• SAMHSA table of changes for the 2024 Part 8 final rule